Literature DB >> 28315321

The functional interplay between the HIF pathway and the ubiquitin system - more than a one-way road.

Julia Günter1, Amalia Ruiz-Serrano1, Christina Pickel1, Roland H Wenger1, Carsten C Scholz2.   

Abstract

The hypoxia inducible factor (HIF) pathway and the ubiquitin system represent major cellular processes that are involved in the regulation of a plethora of cellular signaling pathways and tissue functions. The ubiquitin system controls the ubiquitination of proteins, which is the covalent linkage of one or several ubiquitin molecules to specific targets. This ubiquitination is catalyzed by approximately 1000 different E3 ubiquitin ligases and can lead to different effects, depending on the type of internal ubiquitin chain linkage. The best-studied function is the targeting of proteins for proteasomal degradation. The activity of E3 ligases is antagonized by proteins called deubiquitinases (or deubiquitinating enzymes), which negatively regulate ubiquitin chains. This is performed in most cases by the catalytic removal of these chains from the targeted protein. The HIF pathway is regulated in an oxygen-dependent manner by oxygen-sensing hydroxylases. Covalent modification of HIFα subunits leads to the recruitment of an E3 ligase complex via the von Hippel-Lindau (VHL) protein and the subsequent polyubiquitination and proteasomal degradation of HIFα subunits, demonstrating the regulation of the HIF pathway by the ubiquitin system. This unidirectional effect of an E3 ligase on the HIF pathway is the best-studied example for the interplay between these two important cellular processes. However, additional regulatory mechanisms of the HIF pathway through the ubiquitin system are emerging and, more recently, also the reciprocal regulation of the ubiquitin system through components of the HIF pathway. Understanding these mechanisms and their relevance for the activity of each other is of major importance for the comprehensive elucidation of the oxygen-dependent regulation of cellular processes. This review describes the current knowledge of the functional bidirectional interplay between the HIF pathway and the ubiquitin system on the protein level.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Deubiquitinase; E3 ligase; FIH; Hypoxia; Inflammation; PHD

Mesh:

Substances:

Year:  2017        PMID: 28315321     DOI: 10.1016/j.yexcr.2017.03.027

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  6 in total

Review 1.  The effect of HIF on metabolism and immunity.

Authors:  Cormac T Taylor; Carsten C Scholz
Journal:  Nat Rev Nephrol       Date:  2022-06-20       Impact factor: 42.439

2.  Folic Acid Exerts Post-Ischemic Neuroprotection In Vitro Through HIF-1α Stabilization.

Authors:  Charles K Davis; Sreekala S Nampoothiri; G K Rajanikant
Journal:  Mol Neurobiol       Date:  2018-03-14       Impact factor: 5.590

Review 3.  Hypoxia-Inducible Factor Stabilizers in End Stage Kidney Disease: "Can the Promise Be Kept?"

Authors:  Giuseppina Crugliano; Raffaele Serra; Nicola Ielapi; Yuri Battaglia; Giuseppe Coppolino; Davide Bolignano; Umberto Marcello Bracale; Antonio Pisani; Teresa Faga; Ashour Michael; Michele Provenzano; Michele Andreucci
Journal:  Int J Mol Sci       Date:  2021-11-22       Impact factor: 5.923

Review 4.  Immune and Metabolic Alterations in Liver Fibrosis: A Disruption of Oxygen Homeostasis?

Authors:  Xinyu Li; Quyan Zhang; Zeyu Wang; Quan Zhuang; Mingyi Zhao
Journal:  Front Mol Biosci       Date:  2022-02-03

5.  The Deubiquitinase OTUB1 Is a Key Regulator of Energy Metabolism.

Authors:  Amalia Ruiz-Serrano; Christina N Boyle; Josep M Monné Rodríguez; Julia Günter; Agnieszka E Jucht; Svende Pfundstein; Andreas M Bapst; Thomas A Lutz; Roland H Wenger; Carsten C Scholz
Journal:  Int J Mol Sci       Date:  2022-01-28       Impact factor: 5.923

6.  Glypican-3 Enhances Reprogramming of Glucose Metabolism in Liver Cancer Cells.

Authors:  Gebing Yao; Jikai Yin; Qing Wang; Rui Dong; Jianguo Lu
Journal:  Biomed Res Int       Date:  2019-11-06       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.